Jazz Pharmaceuticals plc (JAZZ)
After hours:
| Previous Close | 107.10 |
| Open | 107.15 |
| Bid | 109.16 x 100 |
| Ask | 109.32 x 100 |
| Day's Range | 107.15 - 109.51 |
| 52 Week Range | 106.61 - 146.70 |
| Volume | |
| Avg. Volume | 621,819 |
| Market Cap | 6.812B |
| Beta (5Y Monthly) | 0.61 |
| PE Ratio (TTM) | 17.91 |
| EPS (TTM) | 6.10 |
| Earnings Date | May 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 188.24 |
PR NewswireJazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2024 first quarter financial results and provide a business and financial update.
- PR Newswire
Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts from across its neuroscience portfolio and pipeline, including two oral presentations, will be featured at the 76th Annual American Academy of Neurology Meeting (AAN) being held April 13-18, 2024, in Denver.
ZacksPharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III
FDA approves AstraZeneca's (AZN) Voydeya (danicopan) in the United States as add on therapy to its other C5 inhibitors. Merck (MRK) begins a phase III study on its oral KRAS G12C inhibitor candidate.
